Drug Profile
Buprenorphine extended release - Foresee Pharmaceuticals
Alternative Names: FP-004Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Foresee Pharmaceuticals
- Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Opioid-related disorders; Pain
Highest Development Phases
- Preclinical Opioid-related disorders; Pain
Most Recent Events
- 10 Oct 2023 Buprenorphine extended release - Foresee Pharmaceuticals is available for licensing as of 10 Oct 2023. https://www.foreseepharma.com/en-us/prores/all
- 10 Oct 2023 Preclinical trials in Opioid-related disorders in USA (SC, Controlled release) (Foresee Pharmaceuticals pipeline; October 2023)
- 10 Oct 2023 Preclinical trials in Pain in USA (SC, Controlled release) (Foresee Pharmaceuticals pipeline; October 2023)